Li Ye-Nan, Zou De-Hui, Gu Min, Mi Ying-Chang, Wang Jian-Xiang, Qiu Lu-Gui
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Zhonghua Nei Ke Za Zhi. 2009 Jun;48(6):481-4.
To investigate the difference of clinical characteristics and outcomes between different isoforms of BCR/ABL in adults with Philadelphia-positive acute lymphoblastic leukemia (ALL).
The data of 106 adults with Ph+ ALL diagnosed in our hospital from January 1, 1996 to December 31, 2007 were reviewed. The difference of clinical characteristics between different subgroups of BCR/ABL was compared and their relation with outcomes was studied.
The median age of the 106 patients was 34 years and the median white blood cell count at baseline was 28.5 x 10(9)/L. Comparative analysis demonstrated that patients in p210 group had an older age, higher blood platelet count (BPC) and more frequent occurrence of splenomegaly. Referring to the outcomes, the complete remission (CR) rate of the two groups were 92.2% and 93.9%, respectively. The median overall survival (OS) and relapse free survival (RFS) in p190 group were 13 months and 10 months, the 1, 3-year estimated OS were (54.7 +/- 6.7)% and (5.5 +/- 5.2)%, and the 1, 3-year estimated RFS were (40.2 +/- 6.8)% and (7.8 +/- 6.7)%, while in p210 group, the median OS and RFS were 15 months and 10 months, respectively, the 1, 3-year estimated OS were (65.8 +/- 8.9)% and (14.5 +/- 7.4)%, and the 1, 3-year estimated RFS were (48.3 +/- 9.4)% and (12.9 +/- 7.7)%. All of the above data had no statistic significance between the two groups.
Majority of the adults with Ph+ ALL is p190 positive and patients with p210 have older age, higher BPC and more frequent occurrence of splenomegaly, while there is no significant difference between p190 group and p210 group in CR rate, RFS and OS.
探讨费城染色体阳性急性淋巴细胞白血病(ALL)成人患者中不同亚型的BCR/ABL临床特征及预后的差异。
回顾性分析1996年1月1日至2007年12月31日在我院确诊的106例成人Ph+ ALL患者的数据。比较BCR/ABL不同亚组之间的临床特征差异,并研究其与预后的关系。
106例患者的中位年龄为34岁,基线时中位白细胞计数为28.5×10⁹/L。对比分析显示,p210组患者年龄较大,血小板计数(BPC)较高,脾肿大发生率更高。在预后方面,两组的完全缓解(CR)率分别为92.2%和93.9%。p190组的中位总生存期(OS)和无复发生存期(RFS)分别为13个月和10个月,1年、3年的估计OS分别为(54.7±6.7)%和(5.5±5.2)%,1年、3年的估计RFS分别为(40.2±6.8)%和(7.8±6.7)%;而p210组的中位OS和RFS分别为15个月和10个月,1年、3年的估计OS分别为(65.8±8.9)%和(14.5±7.4)%,1年、3年的估计RFS分别为(48.3±9.4)%和(12.9±7.7)%。上述所有数据在两组之间均无统计学意义。
大多数成人Ph+ ALL患者为p190阳性,p210患者年龄较大,BPC较高,脾肿大发生率更高,而p190组和p210组在CR率、RFS和OS方面无显著差异。